Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents

Eun Sol Lee; Young June Choe; Seung Ah Choe; Eun Sun Gwak; Donghyok Kwon

doi:10.1097/INF.0000000000004463

Relative Effectiveness of the NVX-CoV2373 Vaccine Compared With the BNT162b2 Vaccine in Adolescents

Pediatr Infect Dis J. 2024 Jul 3. doi: 10.1097/INF.0000000000004463. Online ahead of print.

Authors

Eun Sol Lee¹, Young June Choe², Seung Ah Choe³, Eun Sun Gwak³, Donghyok Kwon¹

Affiliations

¹ From the Division of Epidemiological Data Analysis, Korea Disease Control and Prevention Agency, Cheongju, Korea.
² Department of Pediatrics, Korea University Anam Hospital, Allergy and Immunology Center, Korea University, Seoul, Korea.
³ Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea.

PMID: 38985994
DOI: 10.1097/INF.0000000000004463

Abstract

This retrospective matched cohort study evaluated the efficacy of 2 doses of NVX-CoV2373 compared with that of BNT162b2 vaccines in preventing severe acute respiratory syndrome coronavirus 2 infection in adolescents. We analyzed 13-week risk differences and ratios between these 2 vaccines. The study included 465 NVX-CoV2373 and 465 BNT162b2 recipients. Throughout the follow-up period, 4.1% of NVX-CoV2373 recipients and 2.8% of BNT162b2 recipients contracted the severe acute respiratory syndrome coronavirus 2 infection. The incidence risk ratio for NVX-CoV2373 compared with that for BNT162b2 was calculated at 1.46 (95% CI 0.68-3.22; P = 0.296). While our findings suggest noninferiority between the 2 vaccines, further research is needed to comprehensively assess their effectiveness in real-world settings. Our study highlights the critical need for vigilant vaccine surveillance and monitoring efforts to ensure informed decision-making and public health protection.